Gufic BioSciences Ltd P/E Ratio

The P/E Ratio of Gufic BioSciences Ltd is 41.4 as of 25 Jul 9.00 AM .a1#The P/E Ratio of Gufic BioSciences Ltd changed from 27 on March 2019 to 22.7 on March 2023 . This represents a CAGR of -3.41% over 5 years. a1#The Latest Trading Price of Gufic BioSciences Ltd is ₹ 355.45 as of 25 Jul 15:30 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.3 to 27.3 in 5 years. This represents a CAGR of -0.72%a1# The PE Ratio of Automobile industry is 18.9. The PE Ratio of Finance industry is 23.5. The PE Ratio of IT - Software industry is 29.1. The PE Ratio of Pharmaceuticals industry is 38.6. The PE Ratio of Retail industry is 143.1. The PE Ratio of Textiles industry is 24.3. In 2024a1#The Market Cap of Gufic BioSciences Ltd changed from ₹ 591.9 crore on March 2019 to ₹ 1809 crore on March 2023 . This represents a CAGR of 25.04% over 5 years. a1#The Revenue of Gufic BioSciences Ltd changed from ₹ 195.56 crore to ₹ 195.87 crore over 4 quarters. This represents a CAGR of 0.16% a1#The EBITDA of Gufic BioSciences Ltd changed from ₹ 36.36 crore to ₹ 35.11 crore over 4 quarters. This represents a CAGR of -3.44% a1#The Net Pr of Gufic BioSciences Ltd changed from ₹ 20.62 crore to ₹ 20.05 crore over 4 quarters. This represents a CAGR of -2.76% a1#The Dividend Payout of Gufic BioSciences Ltd changed from 1.78 % on March 2019 to 1.22 % on March 2023 . This represents a CAGR of -7.28% over 5 years. a1#

Gufic Biosciences (GBL) was incorporated in Jul'84. The Company is a result of a reverse merger of itself with Central Finance. The promoters of GBL took over Central Finance at Rs 40-42 per share and then got GBL listed on BSE. Presently, the Company is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. The Choksi and Gandhi family, the promoters of GBL, have a long-standing presence in the pharma industry. In 1960, the family set up a joint venture company called Lyka Labs. In 1976, they decided to part ways and the Choksi family took over the manufacturing facility and the Gufic group of companies was born. Initially known as Gujarat Fine Chemicals, the first foray of the Gufic group was in the manufacture of various bulk drugs. The company later entered the formulation market. Currently, the overall profile of GBL comprises ethical products, herbal products, consumer products and bulk drugs that are sold in the domestic and the international markets. Over the past several years, the company have a known reputation of creating brands that have vaulted to leadership positions in the category in which they have been marketed. To mention a few names: Shapers (sanitary napkins), Onergy, and Stretch nil. In the year 2000, the company issued Bonus Equity Shares in proportion of five Equity shares for every two Equity shares held. Gufic has divested brands in the ethical pharma business in a seller's market. The company plan to invest further in R&D activities and aggressively enter the herbal product and consumer product segments, where it foresee a huge potential. While benefiting from the rich, traditional knowledge base in India, it would like to operate from an area of strength in the herbal products segment. In 2020-21, Gufic Lifesciences Private Limited amalgamated with the Company through the Scheme of Amalgamation which became effective from May 21, 2021. GUFIC UK LIMITED (GUL), a wholly owned subsidiary of the Company, was incorporated in United Kingdom on March 15, 2022. Similarly, in 2023, Gufic Ireland Limited (GIL) was incorporated on March 02, 2023.